To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.

The Alliance for Pharmacy Compounding (APC), a trade organisation representing the compounding industry, has claimed that Novo Nordisk is "confusing the fact that the semaglutide molecule is ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Axplora, a German CDMO that specializes in API small molecule and ADC production, will upgrade its manufacturing facility in ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

Q4 2024 Earnings Call Transcript February 12, 2025 Waters Corporation beats earnings expectations. Reported EPS is $4.1, ...

Closing of the Purchase Agreement will be subject to several closing conditions, including: (i) approval by the shareholders of Steep Hill; receipt of all necessary regulatory approvals, including of ...